Progenics Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Progenics Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed early-phase tilt upper quartile by trial count

Progenics Pharmaceuticals: 8 sponsored US clinical trials, none currently recruiting.

Progenics Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Progressive mCRPC, with 1 trials.

Upper-quartile sponsor footprint

Progenics Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 2

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689
COMPLETED Phase 3

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
COMPLETED Phase 2

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT02981368
COMPLETED Phase 2

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

NCT02020135
COMPLETED Phase 2

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT01695044
COMPLETED Phase 1

Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

NCT01414296
COMPLETED Phase 1

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

NCT01414283
COMPLETED Phase 2

Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

NCT00055185

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 1

Therapeutic Areas

Progressive mCRPC 1
Prostatic Neoplasm 1
Castration-resistant Prostate Cancer 1
Cancer of the Prostate 1
Metastatic Prostate Cancer 1
Prostate Cancer 1

How the Progenics Pharmaceuticals early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Progressive mCRPC (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Progenics Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Progenics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Progenics PharmaceuticalsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Progenics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Progenics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Progenics Pharmaceuticals page

8 registered trials is a research-attention snapshot, not an endorsement of Progenics Pharmaceuticals or any single study.

  • None of Progenics Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Progressive mCRPC is the condition Progenics Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Progressive mCRPC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Progenics Pharmaceuticals pipeline card: 8 registered trials from official public datasets.Report a data error.